Form 4: Viridian Therapeutics Director Acquires Stock Options
SEC Form 4 Filing
Director Jeffrey Robert Ajer acquired 42,000 stock options in Viridian Therapeutics, Inc. on April 7, 2025.
Summary
- On April 7, 2025, Jeffrey Robert Ajer, a director of Viridian Therapeutics, Inc., acquired 42,000 stock options.
- The options have an exercise price of $11.78.
- The options vest in 36 equal monthly installments, contingent upon continued service on the Board of Directors.
- The options expire on April 7, 2035.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard regulatory filing indicating insider activity, which doesn't inherently suggest positive or negative implications.
Positives
- A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- The acquisition of stock options by a director could have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 04/07/2025 | Date of the stock option acquisition. |
| 04/07/2035 | Expiration date of the stock options. |
| 04/09/2025 | Date of the Form 4 filing. |
Keywords
stock options, Form 4, director, Viridian Therapeutics, VRDN, acquisition, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.